SEQUENCE LISTING

<110> CureVac GmbH

<120> Transfection of complexed RNA

<130> CU01P052WO1

<150> PCT/EP2007/007702
<151> 2007-09-04

<160> 44

<170> PatentIn version 3.5

<210> 1
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 1

Arg Arg Arg Arg Arg Arg Arg Arg
1 5

<210> 2
<211> 9
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 2

Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5

<210> 3
<211> 10
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 3

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5 10

<210> 4
<211> 11
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 4

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5 10

<210> 5
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 5

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5 10

<210> 6
<211> 13
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 6

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5 10

<210> 7
<211> 14
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 7

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5 10

<210> 8
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 8

Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg Arg
1 5 10 15

<210> 9

<211> 8
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 9

Lys Lys Lys Lys Lys Lys Lys Lys
1 5

<210> 10
<211> 9
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 10

Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5

<210> 11
<211> 10
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 11

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10

<210> 12
<211> 11
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 12

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10

<210> 13
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 13

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10

<210> 14
<211> 13
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 14

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10

<210> 15
<211> 14
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 15

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10

<210> 16
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 16

Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys Lys
1 5 10 15

<210> 17
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 17

His His His His His His His His
1 5

<210> 18
<211> 9

<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 18

His His His His His His His His His
1 5

<210> 19
<211> 10
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 19

His His His His His His His His His His
1 5 10

<210> 20
<211> 11
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 20

His His His His His His His His His His His
1 5 10

<210> 21
<211> 12
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 21

His His His His His His His His His His His His
1 5 10

<210> 22
<211> 13
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 22

His His His His His His His His His His His His His His
1 5 10

<210> 23
<211> 14
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 23

His His His His His His His His His His His His His His
1 5 10

<210> 24
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<400> 24

His His His His His His His His His His His His His His His
1 5 10 15

<210> 25
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<220>
<221> misc_feature
<223> Xaa = Ornithine

<220>
<221> misc_feature
<222> (1)..(8)
<223> Xaa can be any naturally occurring amino acid

<400> 25

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 26
<211> 9
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<220>
<221> misc_feature
<223> Xaa = Ornithine

<220>
<221> misc_feature
<222> (1)..(9)
<223> Xaa can be any naturally occurring amino acid

<400> 26

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5

<210> 27
<211> 10
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<220>
<221> misc_feature
<223> Xaa = Ornithine

<220>
<221> misc_feature
<222> (1)..(10)
<223> Xaa can be any naturally occurring amino acid

<400> 27

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 28
<211> 11
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<220>
<221> misc_feature
<223> Xaa = Ornithine

<220>
<221> misc_feature
<222> (1)..(11)
<223> Xaa can be any naturally occurring amino acid

<400> 28

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 29

<211> 12
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<220>
<221> misc_feature
<223> Xaa = Ornithine

<220>
<221> misc_feature
<222> (1)..(12)
<223> Xaa can be any naturally occurring amino acid

<400> 29

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 30
<211> 13
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<220>
<221> misc_feature
<223> Xaa = Ornithine

<220>
<221> misc_feature
<222> (1)..(13)
<223> Xaa can be any naturally occurring amino acid

<400> 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 31
<211> 14
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<220>
<221> misc_feature
<222> (1)..(14)
<223> Xaa can be any naturally occurring amino acid

<400> 31

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 32
<211> 15
<212> PRT
<213> Artificial

<220>
<223> Inventive oligopeptide having the general formula:
(Arg)l(Lys(m)(His)n(Orn)o(Xaa)x according to formula I;

<220>
<221> misc_feature
<223> Xaa = Ornithine

<220>
<221> misc_feature
<222> (1)..(15)
<223> Xaa can be any naturally occurring amino acid

<400> 32

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

<210> 33
<211> 13
<212> RNA
<213> Artificial

<220>
<223> Beschreibung der Sequenz: Koszak-Sequenz (s. Beschreibung S. 31)

<400> 33
gccgccacca ugg 13

<210> 34
<211> 15
<212> RNA
<213> Artificial

<220>
<223> Beschreibung der Sequenz: generische Sequenz einer
Stabilisierungssequenz (s. Beschreibung S. 32)

<220>
<221> misc_feature
<222> (1)..(1)
<223> n = C oder U

<220>
<221> misc_feature
<222> (5)..(5)
<223> n = jedes natuerlich auftretende Nukleotid oder ein Analog davon

<220>
<221> repeat_unit
<222> (5)..(5)
<223> x = beliebig

<220>
<221> misc_feature
<222> (9)..(9)
<223> n = U oder A

<220>
<221> repeat_unit
<222> (10)..(10)
<223> x = beliebig

<220>
<221> modified_base
<222> (10)..(10)
<223> n = pyrimidine

<220>
<221> misc_feature
<222> (10)..(10)
<223> n is a, c, g, or u

<220>
<221> misc_feature
<222> (13)..(13)
<223> n = C oder U

<400> 34
nccancccnn ucncc 15

<210> 35
<211> 1882
<212> RNA
<213> Artificial

<220>
<223> description of sequence: construct CAP-Ppluc(wt)-muag-A70-C30

<400> 35
gggagaaagc uuggcauucc gguacuguug guaaagccac cauggaagac gccaaaaaca 60

uaaagaaagg cccggcgcca uucuauccgc uggaagaugg aaccgcugga gagcaacugc 120

auaaggcuau gaagagauac gcccugguuc cuggaacaau ugcuuuuaca gaugcacaua 180

ucgaggugga caucacuuac gcugaguacu ucgaaauguc cguucgguug gcagaagcua 240

ugaaacgaua ugggcugaau acaaaucaca gaaucgucgu augcagugaa aacucucuuc 300

aauucuuuau gccgguguug ggcgcguuau uuaucggagu ugcaguugcg cccgcgaacg 360

acauuuauaa ugaacgugaa uugcucaaca guaugggcau uucgcagccu accguggugu 420

ucguuuccaa aaaggguuug caaaaaauuu ugaacgugca aaaaaagcuc ccaaucaucc 480

aaaaaauuau uaucauggau ucuaaaacgg auuaccaggg auuucagucg auguacacgu 540

ucgucacauc ucaucuaccu cccgguuuua augaauacga uuuugugcca gaguccuucg 600

auagggacaa gacaauugca cugaucauga acuccucugg aucuacuggu cugccuaaag 660

gugucgcucu gccucauaga acugccugcg ugagauucuc gcaugccaga gauccuauuu 720

uuggcaauca aaucauuccg gauacugcga uuuuaagugu uguuccauuc caucacgguu 780

uuggaauguu uacuacacuc ggauauuuga uauguggauu ucgagucguc uuaauguaua 840

gauuugaaga agagcuguuu cugaggagcc uucaggauua caagauucaa agugcgcugc 900

uggugccaac ccuauucucc uucuucgcca aaagcacucu gauugacaaa uacgauuuau 960

cuaauuuaca cgaaauugcu ucugguggcg cucccucuuc uaaggaaguc ggggaagcgg 1020

uugccaagag guuccaucug ccagguauca ggcaaggaua ugggcucacu gagacuacau 1080

cagcuauucu gauuacaccc gagggggaug auaaaccggg cgcggucggu aaaguuguuc 1140

cauuuuuuga agcgaagguu guggaucugg auaccgggaa aacgcugggc guuaaucaaa 1200

gaggcgaacu gugugugaga gguccuauga uuauguccgg uuauguaaac aauccggaag 1260

cgaccaacgc cuugauugac aaggauggau ggcuacauuc uggagacaua gcuuacuggg 1320

acgaagacga acacuucuuc aucguugacc gccugaaguc ucugauuaag uacaaaggcu 1380

aucagguggc ucccgcugaa uuggaaucca ucuugcucca acaccccaac aucuucgacg 1440

caggugucgc aggucuuccc gacgaugacg ccggugaacu ucccgccgcc guuguuguuu 1500

uggagcacgg aaagacgaug acggaaaaag agaucgugga uuacgucgcc agucaaguaa 1560

caaccgcgaa aaaguugcgc ggaggaguug uguuugugga cgaaguaccg aaaggucuua 1620

ccggaaaacu cgacgcaaga aaaaucagag agauccucau aaaggccaag aagggcggaa 1680

agaucgccgu guaauucuag uuauaagacu gacuagcccg augggccucc caacgggccc 1740

uccucccccuc cuugcaccga gauuaauaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1800

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa auauuccccc ccccccccccc ccccccccccc 1860

cccccucuag acaauuggaa uu 1882

<210> 36
<211> 1857
<212> RNA
<213> Artificial

<220>
<223> description of sequence: construct CAP-Ppluc(GC)-muag-A70-C30

<400> 36
gggagaaagc uugaggaugg aggacgccaa gaacaucaag aagggcccgg cgcccuucua 60

cccgcuggag gacgggaccg ccggcgagca gcuccacaag gccaugaagc gguacgcccu 120

ggugccgggc acgaucgccu ucaccgacgc ccacaucgag gucgacauca ccuacgcgga 180

guacuucgag augagcgugc gccuggccga ggccaugaag cgguacggcc ugaacaccaa 240

ccaccggauc gugguugugcu cggagaacag ccugcaguuc uucaugccgg ugcugggcgc 300

ccucuucauc ggcguggccg ucgccccggc gaacgacauc uacaacgagc gggagcugcu 360

gaacagcaug gggaucagcc agccgaccgu gguguucgug agcaagaagg gccugcagaa 420

gauccugaac gugcagaaga agcugcccau cauccagaag aucaucauca uggacagcaa 480

gaccgacuac cagggcuucc agucgaugua cacguucgug accagccacc ucccgccggg 540

cuucaacgag uacgacuucg ucccggagag cuucgaccgg gacaagacca ucgcccugau 600

caugaacagc agcggcagca ccggccugcc gaagggggug gcccugccgc accggaccgc 660

cugcgugcgc uucucgcacg cccgggaccc caucuucggc aaccagauca ucccggacac 720

cgccauccug agcguggugc cguuccacca cggcuucggc auguucacga cccugggcua 780

ccucaucugc ggcuuccggg ugguccugau guaccgguuc gaggaggagc uguuccugcg 840

gagccugcag gacuacaaga uccagagcgc gcugcucgug ccgacccugu ucagcuucuu 900

cgccaagagc acccugaucg acaaguacga ccugucgaac cugcacgaga ucgccagcgg 960

gggcgccccg cugagcaagg aggugggcga ggccguggcc aagcgguucc accucccggg 1020

cauccgccag ggcuacggcc ugaccgagac cacgagcgcg auccugauca cccccgaggg 1080

ggacgacaag ccgggcgccg ugggcaaggu ggucccguuc uucgaggcca agguggugga 1140

ccuggacacc ggcaagaccc ugggcgugaa ccagcggggc gagcugugcg ugcgggggcc 1200

gaugaucaug agcggcuacg ugaacaaccc ggaggccacc aacgcccuca ucgacaagga 1260

cggcuggcug cacagcggcg acaucgccua cugggacgag gacgagcacu ucuucaucgu 1320

cgaccggcug aagucgcuga ucaaguacaa gggcuaccag guggcgccgg ccgagcugga 1380

gagcauccug cuccagcacc ccaacaucuu cgacgccggc guggccgggc ugccggacga 1440

cgacgccggc gagcugccgg ccgcgguggu ggugcuggag cacggcaaga ccaugacgga 1500

gaaggagauc gucgacuacg uggccagcca ggugaccacc gccaagaagc ugcggggcgg 1560

cgugguguuc guggacgagg ucccgaaggg ccugaccggg aagcucgacg cccggaagau 1620

ccgcgagauc cugaucaagg ccaagaaggg cggcaagauc gccguguaag acuaguuaua 1680

agacugacua gcccgauggg ccucccaacg ggcccuccuc cccuccuugc accgagauua 1740

auaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1800

aaaaaauauu cccccccccc cccccccccc cccccccccc ucuagacaau uggaauu 1857

<210> 37
<211> 1653
<212> RNA
<213> Artificial

<220>
<223> description of sequence: coding sequence of the sequence according to SEQ ID NO: 35

<400> 37
auggaagacg ccaaaaacau aaagaaaggc ccggcgccau ucuauccgcu ggaagaugga 60

accgcuggag agcaacugca uaaggcuaug aagagauacg cccugguucc uggaacaauu 120

gcuuuuacag augcacauau cgagguggac aucacuuacg cugaguacuu cgaaaugucc 180

guucgguugg cagaagcuau gaaacgauau gggcugaaua caaaucacag aaucgucgua 240

ugcagugaaa acucucuuca auucuuuaug ccgguguugg gcgcguuauu uaucggaguu 300

gcaguugcgc ccgcgaacga cauuuauaau gaacgugaau ugcucaacag uaugggcauu 360

ucgcagccua ccgugguguu cguuuccaaa aagggguugc aaaaaauuuu gaacgugcaa 420

aaaaagcucc caaucaucca aaaaauuauu aucauggauu cuaaaacgga uuaccaggga 480

uuucagucga uguacacguu cgucacaucu caucuaccuc ccgguuuuaa ugaauacgau 540

uuugugccag aguccuucga uagggacaag acaauugcac ugaucaugaa cuccucugga 600

ucuacugguc ugccuaaagg ugucgcucug ccucauagaa cugccugcgu gagauucucg 660

caugccagag auccuauuuu uggcaaucaa aucauuccgg auacugcgau uuuaaguguu 720

guuccauucc aucacgguuu uggaauguuu acuacacucg gauauuugau auguggauuu 780

cgagucgucu uaauguauag auuugaagaa gagcuguuuc ugaggagccu ucaggauuac 840

aagauucaaa gugcgcugcu ggugccaacc cuauucuccu ucuucgccaa aagcacucug 900

auugacaaau acgauuuauc uaauuuacac gaaauugcuu cugguggcgc uccccucucu 960

aaggaagucg gggaagcggu ugccaagagg uuccaucugc cagguaucag gcaaggauau 1020

gggcucacug agacuacauc agcuauucug auuacacccg agggggauga uaaaccgggc 1080

gcggucggua aaguuguucc auuuuuugaa gcgaagguug uggaucugga uaccgggaaa 1140

acgcugggcg uuaaucaaag aggcgaacug ugugugagag guccuaugau uauguccggu 1200

uauguaaaca auccggaagc gaccaacgcc uugauugaca aggauggaug gcuacauucu 1260

ggagacauag cuuacuggga cgaagacgaa cacuucuuca ucguugaccg ccugaagucu 1320

cugauuaagu acaaaggcua ucagguggcu cccgcugaau uggaauccau cuugcuccaa 1380

caccccaaca ucuucgacgc aggugucgca ggucuucccg acgaugacgc cggugaacuu 1440

cccgccgccg uuguuguuuu ggagcacgga aagacgauga cggaaaaaga gaucguggau 1500

uacgucgcca gucaaguaac aaccgcgaaa aaguugcgcg gaggaguugu guuuguggac 1560

gaaguaccga aaggucuuac cggaaaacuc gacgcaagaa aaaucagaga gauccucaua 1620

aaggccaaga agggcggaaa gaucgccgug uaa 1653

<210> 38
<211> 1653
<212> RNA
<213> Artificial

<220>
<223> description of sequence: the GC-optimized coding sequence of the sequence according to SEQ ID NO: 36

<400> 38
auggaggacg ccaagaacau caagaagggc ccggcgcccu ucuacccgcu ggaggacggg 60

accgccggcg agcagcucca caaggccaug aagcgguacg cccuggugcc gggcacgauc 120

gccuucaccg acgcccacau cgaggucgac aucaccuacg cggaguacuu cgagaugagc 180

gugcgccugg ccgaggccau gaagcgguac ggccugaaca ccaaccaccg gaucguggug 240

ugcucggaga acagccugca guucuucaug ccggugcugg gcgcccucuu caucggcgug 300

gccgucgccc cggcgaacga caucuacaac gagcgggagc ugcugaacag cauggggauc 360

agccagccga ccgugguguu cgugagcaag aagggccugc agaagauccu gaacgugcag 420

aagaagcugc ccaucaucca gaagaucauc aucauggaca gcaagaccga cuaccagggc 480

uuccagucga uguacacguu cgugaccagc caccucccgc cgggcuucaa cgaguacgac 540

uucgucccgg agagcuucga ccgggacaag accaucgccc ugaucaugaa cagcagcggc 600

agcaccggcc ugccgaaggg gguggcccug ccgcaccgga ccgccugcgu gcgcuucucg 660

cacgcccggg accccaucuu cggcaaccag aucaucccgg acaccgccau ccugagcgug 720

gugccguucc accacggcuu cggcauguuc acgacccugg gcuaccucau cugcggcuuc 780

cggguggucc ugauguaccg guucgaggag gagcuguucc ugcggagccu gcaggacuac 840

aagauccaga gcgcgcugcu cgugccgacc cuguucagcu ucuucgccaa gagcacccug 900

aucgacaagu acgaccuguc gaaccugcac gagaucgcca gcgggggcgc cccgcugagc 960

aaggaggugg gcgaggccgu ggccaagcgg uuccaccucc cgggcauccg ccagggcuac 1020

ggccugaccg agaccacgag cgcgauccug aucacccccg agggggacga caagccgggc 1080

gccgugggca aggugguccc guucuucgag gccaaggugg uggaccugga caccggcaag 1140

acccugggcg ugaaccagcg gggcgagcug ugcgugcggg ggccgaugau caugagcggc 1200

uacgugaaca acccggaggc caccaacgcc cucaucgaca aggacggcug gcugcacagc 1260

ggcgacaucg ccuacuggga cgaggacgag cacuucuuca ucgucgaccg gcugaagucg 1320

cugaucaagu acaagggcua ccagguggcg ccggccgagc uggagagcau ccugcuccag 1380

caccccaaca ucuucgacgc cggcguggcc gggcugccgg acgacgacgc cggcgagcug 1440

ccggccgcgg ugguggugcu ggagcacggc aagaccauga cggagaagga gaucgucgac 1500

uacguggcca gccaggugac caccgccaag aagcugcggg gcggcguggu guucguggac 1560

gaggucccga agggccugac cgggaagcuc gacgcccgga agauccgcga gauccugauc 1620

aaggccaaga agggcggcaa gaucgccgug uaa 1653

<210> 39
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of sequence: exemplary oligopeptide according to generic formula (I)

<400> 39

Arg Arg Arg Arg Arg Arg Arg Arg Arg His His His
1 5 10

<210> 40
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of sequence: exemplary oligopeptide according to generic formula (I)

<400> 40

His His His Arg Arg Arg Arg Arg Arg Arg Arg Arg His His His
1 5 10 15

<210> 41
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of sequence: exemplary oligopeptide according to generic formula (I)

<400> 41

Tyr Ser Ser Arg Arg Arg Arg Arg Arg Arg Arg Arg Ser Ser Tyr
1 5 10 15

<210> 42
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of sequence: exemplary oligopeptide according to generic formula (I)

<400> 42

His His His Arg Arg Arg Arg Arg Arg Arg Arg Ser Ser Tyr
1 5 10 15

<210> 43
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of sequence: exemplary oligopeptide according to generic formula (I)

<400> 43

Arg Lys His Arg Lys His Arg Lys His Arg Lys His
1 5 10

<210> 44
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of sequence: exemplary oligopeptide according to generic formula (I)

<400> 44

Tyr Arg Lys His Arg Lys His Arg
1 5